IGF1 and Mental deterioration: These findings provide the impetus for further investigations in larger studies with longitudinal design, to fully comprehend and assess the potential implications of measuring IGF-1 as a biomarker of pathology and the implications of focusing on altering IGF-1 concentrations to prevent the onset of secondary pathologies, particularly cognitive decline, observed in aging adults with CP.